Skip to main content
NewslettersWatchlist

Amgen Inc(AMGN-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low284.14
Day High291.11
Open:288.18
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
Barchart
Options Playbook: Exploring 3 Iron Condor Trade Ideas Amid Market Volatility
Motley Fool
2 Reasons to Buy Amgen Stock, and 1 Reason to Be Cautious
Barchart
Stocks Settle Sharply Lower on the Outlook for Slower Fed Rate Cuts
Baystreet
TSX Lower on Day, Strengthens on Week
Barchart
Stocks Tumble as Hawkish Fed and Strong US Economic News Boosts Bond Yields
Motley Fool
Want Decades of Passive Income? Buy This Index Fund and Hold It Forever
Motley Fool
2 Dividend Stocks to Buy Hand Over Fist in November
Motley Fool
Investors Like Certainty. Trump's Win Gave Them Some.
Motley Fool
Amgen (AMGN) Q3 2024 Earnings Call Transcript
Motley Fool
Stock-Split Watch: 2 Healthcare Stocks That Look Ready to Split
Motley Fool
2 Reliable Dividend Stocks You Can Buy and Hold Forever
BayStreet.ca
Health and Wellness Sector Sees New Opportunities in Weight Loss Drug Market
Barchart
3 Top Healthcare Stocks to Buy for Growth and Dividends
Motley Fool
Is Amgen Stock a Buy?
Barchart
S&P 500 and Dow Jones Industrials Post Record Highs on Earnings Optimism
Barchart
Stocks Climb on Strength in Tech and Earnings Optimism
Barchart
S&P 500 Posts a Record High on Corporate Earnings Optimism
Motley Fool
2 Top Dividend Stocks to Buy Hand Over Fist Right Now
Motley Fool
2 Biotech Stocks to Buy Hand Over Fist in October
Motley Fool
Want to Invest in the Weight Loss Boom? Consider Buying These 2 Stocks
Motley Fool
3 Magnificent Dividend Stocks to Buy in October
Motley Fool
Should You Buy the Dip on This Top Growth Stock?

Profile

Amgen Inc. is the leading biotech companies world wide, with a strong presence in the oncology/hematology, cardiovascular disease, neuroscience, inflammation, bone health & nephrology and neuroscience markets. It developed two most successful drugs, Epogen & Neupogen. Amgen successfully launched two next-generation products, Aranesp & Neulasta and also a biosimilar drug, Prolia/Xgeva. The acquisition of Immunex Corp gave Amgen access to the multi-blockbuster drug, Enbrel. Other products are Repatha, Blincyto, Parsabiv, Evenity, Aimovig, Lumakras/Lumykras, Kanjinti, Mvasi & Amgevita biosimilars. Amgen also has a promising pipeline of cancer drugs. It has one of the strongest cash positions in the biotech sector, which could be used to acquire more pipeline assets that could fuel long-term growth. The erythropoiesis-stimulating agents and granulocyte colony-stimulating factor franchise comprise Epogen/Aranesp and Neupogen/Neulasta respectively. Biosimilar drugs are also a key part of Amgen's growth strategy.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.